Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known whether doxorubicin is more effective than
daunorubicin for AIDS-related Kaposi's sarcoma.
PURPOSE: Randomized double-blinded phase III trial to determine if doxorubicin is more
effective than daunorubicin in treating patients who have AIDS-related Kaposi's sarcoma.